References

Alix-Panabieres C, Pantel K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov. May 2016;6(5):479-491. Available at: http://cancerdiscovery.aacrjournals.org/content/6/5/479.full.

Balaj L, Laurent LC. exRNA website. First CLIA-validated exosome-based clinical liquid biopsy test is launched. Updated January 27, 2016. Available at: https://exrna.org/first-clia-validated-exosome-based-clinical-liquid-biopsy-test-is-launched/.

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. Feb 19 2014;6(224):224ra224. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017867/.

Bhadra K, Mellert H, Pestano, G. Adoption of Liquid Biopsy Tests for NSCLC. Clinical Lab Products [online magazine]. June 5, 2017. Available at: http://www.clpmag.com/2017/06/adoption-liquid-biopsy-tests-nsclc/.

Biocept website. Biocept's Technology and Circulating Tumor Cells (CTCs). Available at: https://biocept.com/technology/.

Butler TM, Spellman PT, Gray J. Circulating-tumor DNA as an early detection and diagnostic tool. Curr Opin Genet Devel. February 2017;42:14-21.

CELLSEARCH^® Circulating Tumor Cell Test website. Available at: https://www.cellsearchctc.com/.

CELLSEARCH^® Circulating Tumor Cell Test website. Menarini-Silicon Biosystems Completes Acquisition of CELLSEARCH^® Assets. BOLOGNA, Italy and Philadelphia, PA. April 3, 2017. Available at: https://www.cellsearchctc.com/menarini-silicon-biosystems-completes-acquisition-cellsearch%C2%AE-assets.

Cleveland Clinic website. Tissue Biopsy. Available at: https://my.clevelandclinic.org/health/diagnostics/15458-biopsy-overview.

Contreras-Naranjo JC, Wu HJ, Ugaz VM. Microfluidics for exosome isolation and analysis-enabling liquid biopsy for personalized medicine. Lab Chip. 2017;17:3558-3577.

Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. August 2013;10(8):472-484.

Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. September 2008;14(9):985–990. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820391/.

Dressman D, Yan H, Traverso G, KInzler KW, Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. July 22, 2003;100(15):8817–8822. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC166396/.

Gingras I, Salgado R, Ignatiadis M. Liquid biopsy: will it be the ‘magic tool’ for monitoring response of solid tumors to anticancer therapies? Current Opinion in Oncology. November 2015;27(6):560-567.

Heitzer E, Ulz P, Geigl JB. Circulating Tumor DNA as a Liquid Biopsy for Cancer. Clin Chem. December 2014;61(1):112–123. Available at: http://clinchem.aaccjnls.org/content/61/1/112.

Insight Pharma Reports. Liquid Biopsy: An Emerging Market for Radically Improved Cancer Management. June 2, 2016. Available at: https://www.globenewswire.com/news-release/2016/06/02/1378669/0/en/Liquid-Biopsy-An-Emerging-Market-for-Radically-Improved-Cancer-Management.html.

Karachaliou N, Mayo-de-las-Casas C, Molina-Vila MA, Rossel R. Real-time liquid biopsies become a reality in cancer treatment. Ann Translation Med. March 2015;3(3):36. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356857/.

Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A. June 7, 2011;108(23): 9530–9535. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111315/.

Krishnamurthy N, Spencer E, Torkamani A, Nicholson L. Liquid Biopsies for Cancer: Coming to a Patient near You. J Clin Med. January 4, 2017;6(1):3. Available at: http://www.mdpi.com/2077-0383/6/1/3/htm#sec4-jcm-06-00003.

Lecomte T, Berger A, Zinzindohoue F, Micard S, Landi B, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Inter J Cancer. June 19, 2002;100(5): 542–548. Available at: https://pubmed.ncbi.nlm.nih.gov/12124803/.

Liquid-biopsy.gene-quantification.info website. Available at: http://liquid-biopsy.gene-quantification.info/.

Mao C, Yuan JQ, Yang ZY, Fu XH, Wu XY, et al. Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis. Medicine. May 2015;94(21):e775. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616411/.

Norton SE, Lechner JM, Williams T, Fernando MR. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clin Biochem. October 2013;46(15):1561–1565. Available at: https://www.sciencedirect.com/science/article/pii/S0009912013002798?via%3Dihub.

Novella Clinical website. The Promise of Liquid Biopsy Technology [whitepaper]. Available at: http://novellaclinical.com/content/uploads/2016/09/Novella_Oncology_Liquid-Biopsy_Whitepaper.pdf.

Pailler E, Adam J, Barthelemy A, Oulhen M, Auger N, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol. Jun 20, 2013;31(18):2273-2281. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23669222.

Perakis S, Speicher MR. Emerging concepts in liquid biopsies. BMC Medicine. 2017;15:75. Available at: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0840-6.

Perez-Callejo D, Romero A, Provencio M, Torrente M. LIquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring. Transl Lung Cancer Res. 2016;5(5):455-465. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099509/.

Perkins G, Yap TA, Pope L, Cassidy AM, Dukes JP, et al. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PloS One. 2012;7(11): e47020. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492590/.

Qin Z, Ljubimov VA, Zhou C, Tong Y, Liang J. Cell-free circulating tumor DNA in cancer. Chin J Cancer. 2016;35:36. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823888/.

Qiu M, Wang J, Xu Y, Ding X, Li M, et al. Circulating Tumor DNA is Effective for the Detection of EGFR Mutation in Non-Small Cell Lung Cancer: A Meta-analysis. Cancer Epidemiol Biomarkers Prev. Jan 2015;24(1):206-212. Available at: http://cebp.aacrjournals.org/content/24/1/206.long.

Rapisuwon S, Vietsch EE, Wellstein A. Circulating biomarkers to monitor cancer progression and treatment. Comput Struct Biotechnol J. June 1, 2016;14:211–222. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913179/.

Roberts PJ. Clinical use of crizotinib for the treatment of non-small cell lung cancer. Biologics. 2013;7:91–101. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643289/.

Roche Molecular Diagnostics website. cobas^® EGFR Mutation Test v2. Available at: https://molecular.roche.com/assays/cobas-egfr-mutation-test-v2-ce-ivd/.

Sasaki T, Rodig SJ, Chirieac LR, Jänne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. July 2010;46(10):1773-1780. Available at: http://www.ejcancer.com/article/S0959-8049(10)00305-9/fulltext.

Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. November 1, 2014;32(31):3483-3489. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209100/.

Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol. September 2006;24(26):4270–4276.

Vallée A, Marcq M, Bizieux A, Kouri C, Lacroix H, et al. Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. Lung Cancer. November 2013;82(2):373–374.

van der Pol E, Böing AN, Harrison P, Sturk A, Nieuwland R. Classification, functions, and clinical relevance of extracellular vesicles. Pharm Rev. July 2012;64(3):676–705. Available at: http://pharmrev.aspetjournals.org/content/64/3/676.

Walker N. "The New Wave in Cancer Screening: Liquid Biopsy Testing." American Pharmaceutical Review. April 30, 2017. Available at: http://www.americanpharmaceuticalreview.com/Featured-Articles/337584-The-New-Wave-in-Cancer-Screening-Liquid-Biopsy-Testing/.

Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nature Reviews Cancer. February 24, 2017;7:223-238.